The irony of chirality - unveiling the distinct mechanistic binding and activities of 1-(3-(4-amino-5-(7-methoxy-5-methylbenzo[b]thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one enantiomers as irreversible covalent FGFR4 inhibitors

被引:26
|
作者
Akher, Farideh Badichi [1 ]
Farrokhzadeh, Abdolkarim [1 ]
Olotu, Fisayo A. [1 ]
Agoni, Clement [1 ]
Soliman, Mahmoud E. S. [1 ]
机构
[1] Univ KwaZulu Natal, Sch Hlth Sci, Mol Biocomputat & Drug Design Lab, Westville Campus, ZA-4001 Durban, South Africa
关键词
SELECTIVE INHIBITOR; OVERCOME RESISTANCE; DISCOVERY; COMPLEX; POTENT; DERIVATIVES; DESIGN;
D O I
10.1039/c8ob02811g
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The influence of chirality on the therapeutic activities of drug molecules has remained an interesting subject matter in drug design. The recent identification of two chiral irreversible inhibitors with differential inhibitory activities towards oncogenic fibroblast growth factor receptor 4 (FGFR4) presented an avenue to investigate the underlying mechanisms that accounted for their disparate activities. Accordingly, the S-configured form (9g) exhibited '15 times' potency than the corresponding R-configured (9h) form. Nonetheless, the big question remains how does chirality influence their inhibitory potencies? Therefore, in this study, we seek to provide useful insights into this interesting phenomenon using molecular dynamics simulations and free binding energy calculations. Interestingly, we observed that the inhibitory 9g activity correlates with a coordinated movement of the active site p-loop, as specifically induced by the S-configuration, which allowed the rotation of three dihedral angles; phi(1(CNCO)), phi(2(CCC*N)) and phi(3(CCCC)), thereby achieving optimal orientations suitable for interactions with crucial active site residues such as LEU473, LYS503, ASP641 and TYR643. Consequentially, while the 9h-bound FGFR4 active site was highly unstable, 9g exerted an inward pulling effect which accounted for active site stability and compactness. Also, the positional movement of 9h (R-configuration) at the active site was restricted, thereby preventing interactions with key residues. Moreover, 9g exhibited the most favorable binding as compared to 9h which showed a relatively lower Delta G(bind). The higher binding affinity of 9g to FGFR4 can be mainly attributed to the increase in van der Waals energy by -4.12 kcal mol(-1) and electrostatic by -2.89 kcal mol(-1). The difference in van der Waals interactions is mainly determined by two residues; ASP641 and TYR643, whilst, the difference in electrostatic interactions is primarily determined by two residues LEU473 and LYS503.
引用
收藏
页码:1176 / 1190
页数:15
相关论文
共 50 条
  • [1] 5-(4-Chlorophenyl)-7-(4-methylphenyl)4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine
    Patel, Urmila H.
    Modh, Rajesh D.
    Shah, Dhaval A.
    ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2013, 69 : O1286 - +
  • [2] Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor
    Chough, Chieyeon
    Joung, Misuk
    Lee, Sunmin
    Lee, Jaemin
    Kim, Jong Hoon
    Kim, B. Moon
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (08) : 1495 - 1510
  • [3] (E)-3-(2H-1,3-Benzodioxol-5-yl)-1-(7-hydroxy-5-methoxy-2,2-dimethylchroman-8-yl)prop-2-en-1-one
    Ahmad, Farediah
    Hashim, Nur Athirah
    Basar, Norazah
    Awang, Khalijah
    Ng, Seik Weng
    ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2011, 67 : O2301 - U2336
  • [4] Discovery of 1-{(3R,4R)-3[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants
    Cheng, Hengmiao
    Nair, Sajiv K.
    Murray, Brion W.
    Almaden, Chau
    Bailey, Simon
    Baxi, Sangita
    Behenna, Doug
    Cho-Schultz, Sujin
    Dalvie, Deepak
    Dinh, Dac M.
    Edwards, Martin P.
    Feng, Jun Li
    Ferre, Rose Ann
    Gajiwala, Ketan S.
    Hemkens, Michelle D.
    Jackson-Fisher, Amy
    Jalaie, Mehran
    Johnson, Ted O.
    Kania, Robert S.
    Kephart, Susan
    Lafontaine, Jennifer
    Lunney, Beth
    Liu, Kevin K-C.
    Liu, Zhengyu
    Matthews, Jean
    Nagata, Asako
    Niessen, Sherry
    Ornelas, Martha A.
    Orr, Suvi T. M.
    Pairish, Mason
    Planken, Simon
    Ren, Shijian
    Richter, Daniel
    Ryan, Kevin
    Sach, Neal
    Shen, Hong
    Smeal, Tod
    Solowiej, Jim
    Sutton, Scott
    Tran, Khanh
    Tseng, Elaine
    Vemier, William
    Walls, Marlena
    Wang, Shuiwang
    Weinrich, Scott L.
    Xin, Shuibo
    Xu, Haiwei
    Yin, Min-Jean
    Zientek, Michael
    Zhou, Ru
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (05) : 2005 - 2024
  • [5] Synthesis of 3-(4-Chloro-2-methoxy-7H-pyrrolo[2,3-d]-pyrimidin-7-yl)propanoic acid - An N(9)-Functionalized 7-Deazapurine
    Rosemeyer, Helmut
    MOLBANK, 2009, (01)
  • [6] Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl) pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC
    He, Linhong
    Li, Da
    Zhang, Chufeng
    Bai, Peng
    Chen, Lijuan
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (17) : 4171 - 4175
  • [7] Covalent Modification of p53 by (E)-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one
    Brown, Kate
    Robello, Marco
    Perciaccante, Andrew J.
    Dinan, Jerry C.
    Maity, Tapan K.
    Lyons, Gaelyn C.
    Kumar, Jay P.
    Durell, Stewart R.
    Tagad, Harichandra D.
    Schilling, Daniel
    Nikolayevskiy, Herman
    O'Connor, Robert
    Appella, Ettore
    Appella, Daniel H.
    Jenkins, Lisa M.
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2024, 7 (11) : 3559 - 3572
  • [8] Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones
    Beckers, Thomas
    Sellmer, Andreas
    Eichhorn, Emerich
    Pongratz, Herwig
    Schaechtele, Christoph
    Totzke, Frank
    Kelter, Gerhard
    Krumbach, Rebekka
    Fiebig, Heinz-Herbert
    Boehmer, Frank-D.
    Mahboobi, Siavosh
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (01) : 125 - 136
  • [9] 7-Benzyl-3-(4-fluorophenyl)-2-(pyrrolidin-1-yl)-5,6,7,8-tetrahydropyrido-[4′,3′:4,5]thieno[2,3-d]pyrimidin-4(3H)-one
    Chen, Hong
    Hu, Hai-Jun
    Yan, Kai
    Dai, Qiu-Hong
    ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2011, 67 : O2228 - U1675
  • [10] 2-(3-{(3R, 4R)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-piperidin-1-yl}oxetan-3-yl)acetonitrile monohydrate
    Gehringer, Matthias
    Pfaffenrot, Ellen
    Keck, Peter R. W. E. F.
    Schollmeyer, Dieter
    Laufer, Stefan A.
    ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2014, 70 : O382 - +